Does She Really Need All These Tablets? - Reflections on the BGS Pragmatic Prescribing Guidance
Author: Seraina Netzer
Afilliations: 1. Department of Geriatrics, Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland; 2. Department of Geriatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 3. Berner Spitalzentrum für Altersmedizin Siloah, BESAS, Gümligen, Switzerland.
An 86-year-old woman with moderate frailty is admitted following a fall. Her medication list includes a statin, osteoporosis treatment, metformin, and all four recommended classes of heart failure medication. Her daughter asks: "Does she really need all of these tablets?"
As geriatricians, we encounter variations of this question almost every day. But the answer is often far from straightforward. Disease-specific guidelines tend to tell us when to start medications, but are often less helpful when frailty, multimorbidity, limited life expectancy and treatment burden enter the picture.
When the British Geriatrics Society published its Pragmatic Prescribing guidance for older people with moderate to severe frailty, I read it with interest. Almost a year later, I have referenced and shared it over and over again.
Some recommendations are straightforward. Reviewing long-term bisphosphonate treatment after several years or reconsidering statins used solely for primary prevention are conversations many geriatricians are already having with their patients.
What I found particularly valuable were the areas where the guidance acknowledges uncertainty. Take heart failure treatment. We have become accustomed to hearing about the "four pillars" of therapy. But the BGS guidance explicitly acknowledges that many people with moderate or severe frailty were underrepresented in the trials underpinning these recommendations and suggests that fewer than all four classes may represent a better balance of benefit and harm.
Colleagues and I had discussed this very issue many times before. Do all four medications always remain necessary in an older person with significant frailty? If not, which should be stopped first? The guidance does not provide a simple algorithm, and perhaps that is the point. Clinical judgement remains essential, but it legitimises a conversation that many clinicians are already having.
In my experience, these discussions are particularly common and important for clinicians working in long-term care. Patients and families frequently express a desire for fewer medications and less treatment burden. The challenge is identifying which medications continue to provide meaningful benefit and which have become part of a regimen simply because they were started years ago.
This is what I appreciate about the BGS guidance. It does not promote therapeutic nihilism or offer simplistic answers. Instead, it provides a pragmatic framework for balancing benefit, harm, patient priorities, and uncertainty.





Comments